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1. INTRODUCTION 
 Oral dosage forms can be grouped as solid, liquid, semi solid and gaseous 
dosage forms. The solid dosage forms are available mostly in unit dosage forms 
(consisting of doses which are taken by numbers) such as tablets, capsules, lozenges 
etc.1. When drugs are administered orally in dry state, tablets and capsules are most 
convenient dosage form.2 Tablets may be defined as solid pharmaceutical dosage 
forms containing drug substance with or without suitable diluents and prepared 
either by compression or molding process3. For all practical purposes only 
compression tablets are almost universally used while molded tablets being a rare 
commodity. Drugs are more frequently taken by oral administration4. 
 Although a few drugs taken orally are intended to be dissolved within the 
mouth, vast majority of drugs taken orally are swallowed.5 Compared with alternate 
routes, the oral route of drug administration is the most popular and has been 
successfully used for the conventional delivery of drug.6 It is considered most 
natural, uncomplicated, convenient, safe means of administering drugs.7 Some of it’s 
advantages are greater flexibility in dosage design, ease of production, low cost etc.8 
Some of the undesirable effects of conventional solid dosage forms can be overcome 
by the use of immediate release tablets.9 Many patients find it difficult to swallow 
tablets and hard gelatin capsules and thus do not comply with prescription which 
result in high incidence of noncompliance and ineffective the therapy. Other 
disadvantages related to conventional oral solid dosage forms are chocking, low 
bioavailability especially drugs which undergo first pass effect (eg. Nitroglycerin) 
delayed absorption etc.10  
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 Recent advances in Immediate Release Drug Delivery Systems aim to 
enhance the safety and efficacy of drug molecule by formulating a convenient 
dosage form for administration and to achieve better patient compliance.11 (Nearly 
35-50% of general population, especially elderly and children suffer from dysphagia 
or difficulty in swallowing ,which results in high incidence of non-compliance and 
ineffective their Swallowing problems are very common in young individuals 
because of their poorly developed muscular and nervous systems12. Other groups 
who may experience the problems in swallowing conventional dosage forms are the 
patients with tremor of extremities, mentally ill, developmentally disabled, non co-
operative and patients with reduced liquid intake or patients suffering from nausea, 
as well as patients travelling or who do not have easy access to water. The 
swallowing problems are also common in some cases such as motion sickness, 
sudden episodes of allergic attack or coughing and due to the lack of water. To 
overcome these problems scientist have developed an innovative drug delivery 
system known as immediate release tablets These are the novel solid oral dosage 
forms which dissolves rapidly in saliva without need for drinking water .The tablet 
disintegrates disintegrates instantaneously or disperse in saliva then swallowed and 
absorbed in normal way. Some drugs are absorbed from mouth, pharynx and 
oesophagus as the saliva passes down in to stomach and produce rapid on set of 
action. (.In such cases bioavailability of drug is significantly greater than those 
observed from conventional tablet dosage forms13. Immediate release tablets with 
good taste and flavor increase the acceptability of bitter drugs by various groups of 
population14.  
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Immediate release Tablets are also known as fast disintegrating Tablet, melt 
in mouth tablet, rapimet, porous tablet, immediate release tablet, Rapidly 
Disintegrating Tablet, orally disintegrating tablet, quick disintegrating tablet, mouth 
dissolving tablet, fast disintegrating tablet15 (United States Pharmacopoeia (USP) 
approved the dosage forms as immediate release tablet .Recently, European 
Pharmacopoeia has used the term immediate release tablet for tablet that disperses 
readily and within 3 minutes in mouth before swallowing. . The disintegration time 
of ODTs generally ranges from several seconds to about a minute16.  
United States Food and Drug Administration (FDA) defined ODT as “A 
solid dosage form containing medicinal substance or active ingredient which 
disintegrates rapidly usually with a matter of seconds when placed up on the 
tongue17. The US Food and Drug Administration centre for Drug Evaluation and 
Research (CDER) defines in the Orange Book an ODT as “A solid dosage form 
containing medicinal substances, which disintegrates rapidly, usually within a matter 
of seconds when placed upon the tongue”. The European Pharmacopoeia defines the 
immediate release, as a tablet that can be placed in the mouth where it disperses 
rapidly, before swallowing18.  
 Immediate release tablets are most widely used dosage form because of it’s 
convenience in terms of self administration, compactness and ease in manufacturing. 
(IRTS rapidly gaining acceptance as an important new drug technology19. These 
dosage forms dissolve or disintegrate in oral cavity within a minute even without the 
need of water or chewing. 
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SIGNIFICANCE OF IMMEDIATE RELEASE TABLETS 20,21 
• They provide good stability, accurate dosing, easy manufacturing small 
packaging size and easy to handle by patients. 
• No risk of obstruction of dosage form, which is beneficial for travelling patients 
who do not have access to water. 
• Easy to administer for pediatric, geriatric and institutionalized patients 
(especially for mentally retarded and psychiatric patients) 
• Rapid disintegration of the tablet results in quick dissolution and rapid absorption 
which provide rapid onset of action.22 
1.1 DESIRED CRITERIA FOR IMMEDIATE RELEASE DRUG DELIVERY 
SYSTEM23,24 
• Requires no water for oral administration 
• Be compatible with taste masking agent 
• Be portable without fragility concern. 
• Have a pleasing mouth feel. 
• Leave minimal or no residue in the mouth after oral administration. 
• Exhibit low sensitivity to environmental conditions like humidity and 
temperature. 
• Allow high drug loading. 
1.2 IMMEDIATE RELEASE TABLETS 
1.2.1 Definition25 
Immediate release tablets are designed to disintegrate and release their 
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medication in absence of any special rate-controlling features as special coating and 
others techniques. 
1.2.2 Advantages of Immediate Release Tablets26,27,28 ; 
1. Large scale manufacturing is feasible in comparison to other dosage forms, 
therefore economy can be achieved. 
2. Accuracy of dosage is maintained since tablet is a solid unit dosage form. 
3. Longer expiry period and microbial spillage owing to lower moisture content. 
4. Easy of packaging(blister or strip)and easy handling over liquid a form. 
5. Easy to transport in bulk. Emergency supplies can be carried by patients29. 
6. Product identification is easy and marking done with the help of grooved 
punched and printing with edible ink, 
1.2.3 Disadvantages of Immediate Release Tablets30,31 ; 
1. It is difficult to convert a high dose poorly compressible API into tablet of 
multiple size for human use32. 
2. Difficult to formulate a drug with poor wettability, slow dissolution in to tablet. 
3. Slow onset of action as compared to parenterals, liquid orals are capsules. 
4. Difficult to swallow for kids, terminally ill and geriatric patients. 
5. Patients undergoing radiotherapy cannot swallow tablet. 
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1.3 FACTORS AFFECTING THE DRUG RELEASE: 33 
1.Physiochemical properties of drug and  
2.Dosage form factors 
The various physiochemical properties of drug that effect drug dissolution 
and its rate are - solubility, partical size, polymorphism, salt form, pseudo-
polymorphism, complexation, wettability etc. 
Dosage form factors include manufacturing process and excipients 
incorporated in them.34 
Several manufacturing process infilence drug dissolution form. processes of 
such importance in manufacturing of tablets are; 
1. Method of granulation 
2. Compression force. 
The excipients such as binders, lubricants, disintegrants, etc influence the 
drug dissolution35. 
The techniques used in the preparation of immediate release tablets are 
1.4 CONVENTIONAL TECHNIQUES:36,37,38, 
1. Tablet molding:  
 In this method, the delivery system is prepared in the form of tablets using 
water soluble additives to allow the tablet to dissolve rapidly and completely in 
mouth. All the ingredients of the formulation are passed through fine mesh, dry 
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blended, wetted with a hydro-alcoholic solvent and then compressed into tablets 
using low compression forces. The solvent is then removed by air drying. 
2. Freezing drying (lyophilization):  
 Lyophilization is a pharmaceutical manufacturing technology, which allows 
drying of heat-sensitive drugs and biologicals at low temperatures under conditions 
that allow removal of water by sublimation. Lyophilization results in preparations, 
which are highly porous, with a very high specific surface area, which dissolve 
rapidly and show improved absorption and bioavailability39. 
3. Spray drying:  
 Spray drying is a process by which highly porous, fine powders can be 
produced. The composition contains a bulking agent (mannitol and lactose), a 
disintegrant (sodium starch glycolate and croscarmellose sodium), an acidic 
ingredient (citric acid) and/ or alkaline ingredients (sodium bicarbonate), which 
when compressed into tablets show fast disintegration and enhanced dissolution40. 
4. Sublimation:  
 This method includes the addition of a sublime salt to the tableting components, 
compressing the blend and removing the salt by the process of sublimation. The active 
ingredient, a diluent, a sublime salt (camphor/ ammonium bicarbonate), a binder and 
other excipients are blended and tablets are prepared. 
5. Addition of disintegrants:  
 Addition of disintegrants in fast dissolving tablets, leads to quik 
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disintegration of tablets and hence improves dissolution. Microcrystalline cellulose, 
cross-linked carboxy methyl cellulose sodium, cross-linked polyvinyl pyrrolidone 
and partially substituted hydroxy propyl cellulose, absorb water and swell due to 
capillary action and are considered as effective disintegrants in the preparation of 
fast dissolving tablets41. 
6. Sugar based excipient:  
 Sorbitol, mannitol, dextrose, xylitol, fructose, maltose and polydextrose 
have been used as bulking agents. Because of their high aqueous solubility and 
sweetness, which impart a pleasing mouth feel and good taste masking, nearly all 
formulations for rapidly dissolving tablets contain sugar-based materials42. 
7. Mass Extrusion:  
 This technology involves softening the active blend using the solvent, 
mixture of water soluble polyethylene glycol using methanol and expulsion of 
softened mass through the extruder or syringe to get a cylinder of the product and 
cutting into even segments upon heated blade to form tablets. 
1.5 OTHER METHODS43 
 Other methods includes dry granulation, wet granulation and direct 
compression methods. The important component used in these methods is super 
disintegrant. 
1.5.1 Dry Granulation 
 In this technique there is no use of liquids. The process involves the 
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formation of slugs. Then slugs are screened or milled to produce granules. The 
granules formed are then compressed to form tablets. 
1.5.2 Wet Granulation 
 The process involves addition of liquid to a powder in a vessel equipped with 
any type of agitation that will produce agglomeration or granules. These granules 
after drying are compressed to form tablets. This method have more operational 
manipulations and is more time consuming than other methods. This method is not 
suitable for drugs which as thermo labile or hydrolysable by presence of water in the 
liquid binder. 
1.5.3 Direct Compression  
 The method involves direct compression of powder blends of active 
ingredient and suitable excipients, which will flow uniformly in the die cavity and 
forms a firm compact44. Direct compression methods are very popular because it 
reduces the number of steps involved and the materials required. 
1.6 SUPER DISINTEGRANTS 
 Disintegrants have a major in the disintegration and dissolution process of 
orodispersible tablets made by direct compression 45. The choice of a suitable type 
and optimal amount of disintegrant is important for ensuring high disintegration rate. 
The addition of other formulation components such as water soluble excipient or 
effervescent agents further enhance dissolution or disintegration properties46 . 
The understanding of disintegrant properties and their effect on formulation 
has advanced significantly during last few years practically regarding 
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superdisintegrants47..  
Addition of super disintegrants in ODTs leads to quick disintegration of 
tablets and hence improves dissolution. Microcrystalline cellulose, crosslinked 
carboxy methyl cellulose sodium, crosslinked Polyvinyl pyrrolidone and partially 
substituted hydroxy propyl cellulose etc absorb water and swell due to capillary 
action and are considered as effective disintegrants in the preparation of fast 
dissolving tablets48. 
Table No-1 : List of Superdisintegrants49 
Superdisintegrants 
Synthetic super disintegrants Example Mechanism of action 
Croscarmellose® Cross linked Cellulose Swelling and wicking 
Crospovidone Cross linked PVP Very little swelling, act by capillary action. 
Sodium starch glycolate Cross linked starch Swelling 
Alginic acid NF Cross linked Alginic 
acid 
Rapid swelling ,wicking 
action 
Natural super disintegrants   
Soy poly saccharides - - 
Calcium silicate (20 – 40 % )  Wicking action 
 
1.7 TECHNIQUES FOR SOLUBILITY ENHANCEMENT50,51 
There are various techniques available to improve the solubility of poorly 
soluble drugs. Some of the approaches to improve the solubility are:  
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1.7.1 Physical Modifications 
A. Particle size reduction  
a. Micronization  
b. Nanosuspension  
B. Modification of the crystal habit  
a. Polymorphs  
b. Pseudopolymorphs  
C. Drug dispersion in carriers  
a. Eutectic mixtures  
b. Solid dispersions  
c. Solid solutions  
D. Complexation  
a. Use of complexing agents  
E. Solubilization by surfactants:  
a. Microemulsions  
b. Self microemulsifying drug delivery systems  
1.7.2. Chemical Modifications 
Solid Dispersion Technology52: 
The term solid dispersion refers to the dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state, prepared by the melting, 
solvent, fusion method, hot melt extrusion or supercritical fluid methods. The term 
co-precipitate has also been frequently used when solid dispersion is prepared by 
solvent method. During the past four decades, the solid dispersion technology was 
used to increase the dissolution rate and bioavailability of poorly water soluble 
drugs13. Some other techniques like salt formation, solubilization and particle size 
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reduction have been employed to increase dissolution rate and bioavailability but 
there are some practical limitations. 
In 1961, Sekiguchi and Obi developed a solid dispersion method to increase 
bioavailability of poorly soluble drugs. This method involves formation of eutectic 
mixture of drug with water-soluble carriers by melting of their physical mixture. 
When the dispersion comes in contact with aqueous fluid, the carrier starts to 
dissolve followed by the release of drug in very fine colloidal particle form because 
of the formation of particles having the greatly enhanced surface area, the 
dissolution rate and solubility increases. Examples: Gris-PEG [Novartis] Nabilone in 
Povidone solid dispersion [Cesamet, Lilly] However, recently sustained release solid 
dispersions are developed using certain type of water insoluble carriers and water 
swellable carriers like, Methocel, Ethocel, Polyox, Carbopol, Klucel, Cellulose 
acetate phthalate, carboxymethyl cellulose. This approach consume less polymer in 
order to control the drug release rate, compared with physical mixture of drug and 
polymer. The solid dispersion can be prepared by fusion method, melting method, 
Solvent method, Hot melt extrusion and supercritical fluid method. 
a. Fusion method: 
The fusion method is sometime referred to as the melting method only if the 
starting material is crystalline. In this method, the carrier is heated to a temperature 
just above its melting point and the drug is incorporated in to the matrix. The 
mixture is cooled with constant stirring in order to obtain homogeneously disperse 
matrix. The first dispersion of sulfathiazole and urea was prepared by fusion 
method, by melting at the eutectic composition followed by cooling step. The 
eutectic composition was choosen to obtain simultaneous crystallization of drug and 
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matrix during cooling. Polymers like Polyethylene glycols and Poly (vinyl 
pyrollidone) PVP are mostly used in this method. 
Limitations: 
 This method is suitable if the drug and polymer are compatible and can be mixed 
homogeneously at the heating temperature in order to prevent formation of two 
incompatible liquid phases or a suspension in heated mixture. This problem can 
be overcome by using surfactants. 
 Sometime may be a problem during cooling stage when the drug-matrix 
miscibility changes which may produce phase separation. This problem is 
observed when cooling is done at slow rate, resulting in formation of crystalline 
drug. This problem can be overcome by implementing faster cooling rate in 
order to form amorphous solid dispersion. 
 This method is not suitable if the carrier is high-melting solid and the drug is 
heat sensitive. 
b. Hot melt extrusion method: 
This method is same as fusion method except that the intensive mixing is 
induced by the extruder. The twin-screw extruder or single-screw extruder is used in 
this method. This method offers the potential to shape the heated mixture in to 
implants, implants inserts, oral dosage forms. To predict the solid-state solubility 
and to select matrix suitable for melt extrusion, the solubility parameters are 
investigated. High shear forces resulting in high temperature in extruder may create 
a problem for heat sensitive materials. The main advantage is the handling of 
product is easier because at the outlet of the extruder the shape can be adapted to the 
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next processing step without grinding. The polymers like Hydroxypropyl cellulose, 
Hydroxypropyl cellulose phthalate, Eudragit, Cellulose acetate phthalate (CAP), 
Poly vinyl alcohol (PVA), and Hydroxypropyl cellulose (HPC) can be used. Leing 
Wang, et al., have prepared solid dispersion of Nitredipine with silica particles using 
the melt mixing method 
c. Solvent method: 
In this method, the carrier and the active ingredients are dissolved in suitable 
organic solvent. The second step involves the removal of solvent(s) under vaccume 
(sometime heat may be applicable with vaccume). When the solvent evaporates, 
super saturation may occur followed by simultaneous precipitation of the 
constituents resulting in a solid residue. During formulation, the formulation 
scientist has to face two challenges;  
 It is difficult to mix drug and polymer in one solution having different polarity. 
 It is difficult to prevent phase separation during removal of solvent(s). 
 The recovery of solvent from coprecipitate takes longer time 
Example53: 
Ethanol: -5°C and reduced pressure followed by drying for 12 h in vacuum 
Methanol/Chloroform: 115°C for 1 hour or 125°C for 25 min from Griseofulvin- 
PEG 6000 dispersion. Drying at high temperature speeds up the drying process and 
reduces the time available for phase separation. On the other hand, high temperature 
speeds up the phase separation (example: crystallization) because of the increase in 
the mobility of drug and polymer.  
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Sometime solvent evaporation could be increased by using rotary evaporator 
followed by storing the residue in a vaccum desiccator to remove the residual 
solvent. Sometime vaccum drying at elevated temperature may cause phase 
separation because the mobility of drug and matrix decreases slowly. The freeze 
drying method can be used to evaporate the solvent hence the solvent should have 
high melting point and high vapor pressure.  
For example: Dimethyl sulfoxide (DMSO) has high melting point (190' C) 
but it has very low vapor pressure (0.08 kPa) hence not suitable solvent, but 2-
methyl-2- propanol or tertiary butanol (TBA) is suitable solvent because it has high 
melting point (125° C) and vapor pressure (5.49 kPa). 
Advantages: 
 Minimal thermal stress during preparation. 
 Reduction in chances of phase separation. 
d. Supercritical fluid method:54 
In this method carbon dioxide is used either as solvent for drug and polymer 
or as an anti-solvent. When carbon dioxide is used as a solvent, the solution mixture 
of carbon dioxide with drug and polymer is sprayed through nozzle into an 
expansion vessel with lower pressure and resulting in formation of particles. As this 
technique does not involve use of any organic solvent termed as "Solvent free 
technique" and also known as Rapid Expansion of Supercritical Solution (RES). The 
application of this technique is very limited because most of the pharmaceutical 
compounds have very low solubility in carbon dioxide solution (less than 0.01 % 
wt). 
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 Advantages of Solid Dispersion Technology: 
 Single formulation can be used for multiple dose formulation 
 Improves bioavailability of drug 
 Improves dissolution of poorly water soluble drugs 
 Controlled release formulations can be formulated Minimal use of excipients 
 Less expensive machines needed during formulation 
 Low cost and profitable production 
Breakthrough in Solid Dispersion Technology: 
Recently, the primary goal of pharmaceutical industry is to discover a new 
chemical entity that would be safe and effective. Initially, because of the limited 
bulk drug supply and accelerated time line would not allow formulator to formulate 
solid dispersion formulations. Even though, the below two recent breakthroughs in 
the formulation of solid dispersion technology have renewed the interest for use in 
commercial development of drug product. 
The development of technology to fill solid dispersion directly into hard 
gelation capsules. For example: Chatham prepared PEG-based solid dispersion by 
filling drug-PEG melts in hard gelatin capsules followed by solidification at room 
temperature. The availability of surface-active and self-emulsifying carriers For 
example: Gelucire 44/14, Polysorbate 80. 
Law et al. demonstrated that by incorporating nifedipine with PEG based 
solid dispersion and 5%(w/w) phosphodityl choline may increase dissolution rate 
more than two folds.  
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The availability of surface-active and self-emulsifying agent may help to 
increase bioavailability of the drug. 
 For example: The bioavailability of ritronavir (solubility<lmcg/ml at pH.2) 
[Norvir®, Abbot Lab] was enhanced by incorporating dispersion into 
mixture of surfaceactive carriers as Gelucire 50/13, Polysorbate 80, and 
Polyoxyl 35 castoroil. 
Table No 2: Commercially immediate release Tablets 
Technologies Trade Name Active Ingredient Manufacturer 
Freeze Drying 
Feldene Fast 
Melt Piroxicam Pfizer, USA 
Claritin Red 
i Tab Loratidine 
Schering plough, 
USA 
Maxalt MLT Rizatriptan Merck, USA 
Z 
Yprexia Olanzepine Eli Lilly, USA 
Pepcid RPD Famotidine Merck, USA 
Zofran ODT Ondansetron Glaxo, UK 
Zooming ZMT Zolmitriptan AstraZeneca, USA 
Zelapar TM Selegilline Amarin,UK 
Disintegrant 
Addition 
Tempra 
Quicklets Acetaminophen Bristol Myers, USA 
Febrectol Paracetamol Prographarma, France 
Nimulid MDT Nimesulide Panacea Biotech, India 
Torrox MT Rofecoxib Torrent pharma, India 
Olanex Instab Olanzapine Ranbaxy, India 
Romilast Montelukast Ranbaxy, India 
Sugar Based 
Excipient 
Benadryl 
Fastmelt 
Diphenhydramine 
& Pseudoephedrine 
WarnerLambert, 
USA 
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Cardiovascular diseases are one of the life threatening diseases of mankind 
and hypertension is the most common cardiovascular disease, which requires 
constant monitoring. It is well known that hypertension is a major factor for 
congestive cardiac failure and coronary artery disease.55 
Hypertension or high blood pressure is a condition in which the blood 
pressure in the arteries is chronically elevated. With every heart beat, the heart 
pumps blood through the arteries to the rest of the body. Blood pressure is the force 
of blood that is pushing up against the walls of the blood vessels. If the pressure is 
too high, the heart has to work harder to pump, and this could lead to organ damage 
and several illnesses such as heart attack, stroke, heart failure, aneurysm, or renal 
failure. 
 The current definition (WHO,2004) of hypertension is level of systolic blood 
pressure of 140 mm Hg or above, a level of diastolic pressure of 90 mm Hg or 
above, by repeated measurement over periods of several weeks. It may be systolic or 
diastolic, diastolic hypertension when diastolic BP is found to be 90 mm Hg or more 
on two consecutive visits. 
1.8.1 Classification of hypertension:56 
 Hypertension is classified as either primary (essential) hypertension or 
secondary hypertension. About 90-95% of cases are categorized as “primary 
hypertension” which means high blood pressure with no obvious medical cause14. 
 The remaining 5-10 % of cases (secondary hypertension) are caused by other 
conditions that affect the kidneys, arteries, heart or endrocrine system. 
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 Persistent hypertension is a major risk factor for stroke, myocardial infarction 
(heart attacks), heart failure and aneurysms of the arteries (e.g. aortic aneurysm), and 
is a cause of chronic kidney disease. Even moderate elevation of arterial blood 
pressure is associated with a shortened life expectancy. Dietary and lifestyle changes 
can improve blood pressure control and decrease the risk of associated health 
complications, although drug treatment is often necessary in patients for whom 
lifestyle changes prove ineffective or insufficient. 
Category Systolic (mm of Hg) Diastolic (mm of Hg) 
Normal >130 <85 
High Normal 130-139 85-89 
Hypertension   
Mild stage (stage 1) 140-159 90-99 
Moderate (stage 2) 160-179 100-109 
Severe (stage 3) 180-209 110-119 
Very sever (stage 4) >210 >120 
Malignant hypertension >200 >140 
 
1.8.2 Etiology:  
In the year 2006 it is estimated that nearly one billion people or ~26% of the 
adult population had hypertension worldwide. It was common in both developed 
(333 million) and undeveloped (639 million) countries. However rates vary 
markedly in different regions with rates as low as 3.4% (men) and 6.8% (women) in 
rural India and as high as 68.9% (men) and 72.5% (women) in Poland.  
In 2001 it is estimated that 43 million people in the United States had 
hypertension or were taking antihypertensive medication, almost 24% of the adult 
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population16. The prevalence of hypertension in the United States is increasing and 
reached 29% in 2004.It is more common in blacks and native Americans and less in 
whites and Mexican Americans, rates increase with age, and is greater in the 
southeastern United States. Hypertension is more prevalent in men (though 
menopause tends to decrease this difference) and those of low socioeconomic status. 
Over 90–95% of adult hypertension is essential hypertension. One of the 
most common causes of secondary hypertension is primary aldosteronism17.  
1.8.3 Antihypertensive agents57:  
Antihypertensive agents are the drugs which lower the blood pressure in 
hypertensive patients. Proteins, peptides and recombinant drugs: 
a. Classification of antihypertensives: 
1. Diuretics 
eg. Chlorthalidone, Clopamide, Indapamide 
2. β Adrenergic blockers 
eg.Acebutolol, Atenolol, Metoprolol, Propranolol, Timolol 
3. α Adrenergic blockers 
eg. Terazosin, Prazosin, Doxazosin 
4. α + β Adrenergic blockers 
eg. Labetalol, Carvedilol,nebivolol 
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5. Ace inhibitors 
eg. Perindopril, Captopril, Enalapril, Lisinopril, Fosinopril, trandolapril, 
benazepril etc. 
6. Calcium channel blockers 
eg. Amlodipine, Felodipine Nifedipine, Nimodipine, Verapamil 
7. Vasodilators 
eg. Hydralazine, Minoxidil, Sodium nitroprusside 
8. Angiotension-II receptor antagonists 
eg. Candesartan, Losartan, Valsartan 
9. Central sympatholytics 
eg. Clonidine, Methyldopa 
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2. LITERATURE REVIEW 
• Calò et al., (1998)58 were studied that the antihypertensive and metabolic effects 
of nebivolol in hypertensive patients with type 1 diabetes. Author shown that the 
drug normalizes blood pressure, and while no improvement in glucose control 
was observed, it reduced total cholesterol and increased HDL cholesterol as well 
as the HDL to total cholesterol ratio. 
• Shougo Kaneko et al., (1999) investigated the renal protective effect of 
nifedipine (2-nitrophenyl derivative BAY a 1040) in streptozotocin (STZ) - 
induced spontaneously hypertensive rats (SHRs, 8 weeks of age). Author 
suggested that nifedipine inhibits the development of albuminuria and 
glomerular enlargement in STZ-induced diabetic SHRs.  
• Istvan Edes et al., (2005) examined the effect of the beta1-selective beta- 
blocker nebivolol, administered as add-on therapy, on left ventricular function in 
260 elderly patients (N65 years) with chronic heart failure (CHF).  
• Zahid Dhakam et al., (2008) reported that nebivolol and atenolol have similar 
effects on brachial blood pressure and aortic stiffness. However, nebivolol 
reduces aortic pulse pressure more than atenolol, which may be related to a less 
pronounced rise in AIx and bradycardia. 
• P. V. Swamy et al., (2007),59 prepared rapidly disintegrating oral tablets of 
meloxicam by direct compression method using superdisintegrants such as 
sodium starch glycolate, Ac-Di-sol and low molecular weight hydroxy propyl 
methyl cellulose. Combinations of superdisintegrants were used along with 
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directly compressible mannitol to enhance mouth feel. The prepared batches of 
tablets were evaluated for hardness, friability, drug content uniformity, wetting 
time water absorption ratio and in-vitro dispersion time. 
• USPTO Patent 20070086974, (2007)60,described about pharmaceutical 
compositions of substituted benzhydrylpiperazines or their pharmaceutically 
acceptable salts, and their methods. It involves formulation of stable and 
palatable taste masked pharmaceutical compositions of cetirizine in combination 
with resins and the process for preparing the same. 
• Keith J. Simons et al., (2006), formulated fast-disintegrating sublingual tablets 
0f Epinephrine bitartrate. Four tablet formulations, A, B, C, and D, containing 
0%, 6%, 12%, and 24% of Epinephrine bitartrate, respectively, and 
microcrystalline cellulose: low-substituted hydroxypropyl cellulose (9:1), were 
prepared by direct compression, at a range of compression forces. Tablet weight 
variation, content uniformity, hardness, disintegration time, wetting time, and 
friability were measured for each formulation at each compression force. All 4 
tablet formulations at each compression force were within the USP limits for 
weight variation and content uniformity. At a mean ± SD hardness of ≤ 2.3 ± 0.2 
kg, all tablet formulations passed the USP friability test. At a mean ± SD 
hardness of ≥ 3.1 ± 0.2 kg, all tablet formulations resulted in disintegration and 
wetting times of <10 seconds and <30 seconds, respectively.  
• Istvan Edes et al., (2005)61 examined the effect of the beta1-selective beta- 
blocker nebivolol, administered as add-on therapy, on left ventricular function in 
260 elderly patients (N65 years) with chronic heart failure (CHF).  
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• Zahid Dhakam et al., (2008) reported that nebivolol and have similar effects on 
brachial blood pressure and aortic stiffness. However, nebivolol reduces aortic 
pulse pressure more than atenolol, which may be related to a less pronounced 
rise in AIx and bradycardia.  
• Sarah E. Capes et al., (2000)62 reported that clinical proteinuria patients with 
left ventricular (LV) dysfunction are unknown. Clinical proteinuria is an 
independent predictor of hospitalization for CHF and mortality in diabetic and 
nondiabetic patients with LV dysfunction. Enalapril significantly reduces the 
risk of clinical proteinuria in diabetic patients with LV dysfunction. 
• Anna K. Trauernicht et al., (2003) were studied that effects of chronic 
treatment with enalapril on cerebrovascular dysfunction and endothelial nitric 
oxide synthase (eNOS) protein in diabetic rats. These results suggested that 
enalapril prevents cerebrovascular dysfunction in diabetic rats. Author conclude 
that the protective role of enalapril may be independent of an alteration in eNOS 
protein in cerebral microvessels.  
• Jeevana Jyothi et al., (2010) developed fast dissolving tablets of nebivolol 
using crospovidone and it’s kneading Mixture. 
• K. Danjo et al., (2002)63 provides information regarding preparation evaluation 
and optimization of rapidly disintegrating tablets. 
• M M Patel et al., (2006) prepared rapid disintegrating tablets of nebivolol by 
using various superdisintegrants following direct compression technique.  
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• Martin et al., (2004) reviewed the nebivolol and their uses. It provides 
information regarding the history preparation, complex formation of nebivolol 
and industrial applications. 
• Pisal et al., (2004)64 formulated and evaluated tasteless complexes of 
Ciprofloxacin with Indione 234. Studies showed that solid dispersion affected by 
pH, but temperature not affected. Volunteers rated the complex as tasteless. 
• Rao et al., (2000) formulated taste masked oral suspension of Quinine sulfate. 
For taste masking solid dispersion was done with ion exchange resin (Indione – 
234). The products were evaluated for bitterness, drug content, particle size, 
viscosity, sedimentation time, volume, redispersibility and drug release. 
• Ronchi M et al., (2003) provides the information regarding the use of 
disintegrants in solid dosage forms. Described the mechanism of disintegrants in 
disintegration process of tablets. 
• S.K Seth et al., (2010) al provides methods to mask the bitter taste of drugs – by 
solid dispersion with beta nebivolol, also described the methods of preparation 
and evaluation of immediate release tablets.  
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3. AIM AND OBJECTIVE 
 The aim of the present work is to investigate the possibility of obtaining 
immediate release tablet of nebivolol with improved dissolution using solid 
dispersion technique. 
Basic goals in the development of immediate dissolving tablet are to increase 
patient compliance, ease of administration, safety and appropriate dosing. Orally 
disintegrating formulations also provide benefits for pharmaceutical companies like 
lifecycle management, line extension, market expansion, cost effective drug 
development programs. 
According to BCS classification nebivolol coming under class 2 category 
which has low solubility and high permeability. Nebivolol is a white powder, 
relatively insoluble in water. Solubility and dissolution was improved by 
formulating solid dispersion. Keeping in view the advantages of this delivery 
system, in the present study, attempts were made to formulate immediate dissolving 
tablet nebivolol, which is useful to reduce blood pressure level in the treatment of 
antihypertensive agents. 
The direct compression was used to compress the tablets as it is the easiest 
way to manufacture tablets. Conventional equipments, commonly available 
excipients and limited number of processing steps are involved in direct 
compression and so manufacturing cost is low. Tablets produced by direct 
compression are relatively strong in hardness and have less friability. 
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Super disintegrants are the major components of immediate release 
tablets.Based on their origin they can be grouped in to two category, synthetic super 
disintegrants (micro crystalline cellulose, cross povidone, cros carmellose sodium, 
starch glycolate) and natural super disintegrants. 
Natural origin is preferred over semi synthetic and synthetic substances 
because they are comparatively cheper, abundantly, non irritating non toxic in 
nature. 
The formulation of immediate release using natural super disintegrants is an 
excellent example for the application of natural agents in the formulative field. And 
this proved that the natural agents have almost equivalent properties to synthetic 
agents, which can be widely used for formulation of dosage forms. 
Nebivolol used to improve the solubility, stability of drug and also to mask 
its bitter taste. 
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4. PLAN OF THE WORK 
 LITERATURE SURVEY 
 SELECTION OF DRUG AND EXCIPIENTS 
 PREFORMULATION STUDIES 
o Evaluation of Physical Parameters of Nebivolol 
o Drug Excipients Compatibility study 
o Construction of standard curve 
 PREPARATION OF SOLID DISPERSION AND PHYSICHAL 
MIXTURE 
 CHARACTERISATION OF SOLID DISPERSION AND PHYSICAL 
MIXTURE 
 PREPARATION AND EVALUATION OF NATURAL 
SUPERDISINTEGARANTS  
 PRECOMPRESSION PARAMETERS 
 FORMULATION OF IMMEDIATE RELEASE TABLETS WITH 
DIFFERENT DISINTEGRANTS 
 EVALUATION OF IMMEDIATE TABLETS BY  
o Weight variation 
o Friability 
o Thickness 
o Hardness 
o In-vitro disintegration  
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o Wetting time  
o Uniformity of dispersion  
o Water absorption ratio 
o Assay 
o In-vitro dissolution study 
 STABILITY STUDY OF OPTIMISED FORMULAITON AS PER ICH 
GUIDELINES 
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5.1 DRUG PROFILE:
5.1.1 NEBIVOLOL65,66
Nebivolol is a highly car
in treatment of hypertension.
Chemical Structure: 
Chemical Name: 
1,1’-(bis(6-fluoro-3,4-
Molecular Formula: 
Molecular Weight: 405.4
Category: selective beta
Description: white to almost 
Solubility:  
The solubility of drug was determined in various solvents and it was found 
that the drug is freely soluble in N,
sulfoxide; sparingly soluble in polypropylene glycol and ethanol and insoluble in 
water. 
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Storage:  
Store below 30oc, protect from moisture. Store in tight light resistant 
container. 
Mechanism of action:  
Nebivolol is a selective , β1, - receptors antagonist. activation of receptors by 
epinephrine increase the heart rate and blood pressure, and the heart consumes more 
oxygen. nebivolol blocks these receptor which reverse effect of epinephrine, 
lowering the heart rate and blood pressure. in addition, beta blockers prevent the 
release of resin, which is a hormone produced by the kidneys which leads to 
construction of blood pressure. A enough concentration, this drug may also bind 
bete2 receptors.  
Pharmacodynamics: 
Nebivolol is a competitive and highly selective beta-1 receptor antagonist 
with mild vasodilating properties, its due to an interaction with the L-arginine\nitric 
acid pathway. In preclinical studies, nebivolol has been show induse endothelium-
dependent arterial relaxation in a dose dependent manner, by stimulation of the 
release endothelial nitric oxide. Nictric acid acts to relax vascular smooth muscle 
cells and inhibits platelets aggregation adhesion.  
 Renal effects: 
 Plasma concentrations of nebivolol have been reported to be increased in 
patients with renal impairment. Based on mean AUC data, approximately 40% to 
50% higher plasma concentrations of nebivolol were observed in hypertensive 
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patients with moderate to severe renal impairment compared to a control group of 
hypertensive patients with normal renal function. 
Pharmacokinetics: 
Absorption 
Nebivolol is rapidly and extensively absorbed following oral administration, 
with absolute bioavailability of approximately 25% to 35% due to a significant 
degree of first-pass metabolism. When administered with food, the rate of absorption 
is slowed, as evidenced by a delay in the time to reach peak plasma levels, with no 
significant difference in extent of bioavailability. 
Distribution 
The drug is highly lipophilic and is highly protein bound. The stereo 
selective tissue distribution of nebivolol enantiomers results from an enantiomeric 
difference in plasma protein binding rather than in tissue binding.  
Metabolism 
Nebivolol is metabolized primarily by aromatic ring oxidation and 
glucuronidation.The oxidative metabolites are further metabolized by conjugation 
via glucuronidation and sulfation. Demethylation and hydroxylation at the phenol 
ring produce 3 active metabolites with β-receptor blocking activity. Based on 
preclinical studies, the 4'-hydroxyphenyl metabolite is approximately 13 times more 
potent than nebivolol for β-blockade. Compared to nebivolol, the 3 active 
metabolites exhibit weak vasodilating activity. Plasma concentrations of the active 
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metabolites are about one-tenth of those observed for nebivolol and have 
pharmacokinetics similar to the parent. 
Elimination 
The metabolites of nebivolol are excreted primarily via the bile into 
the feces. The elimination half-life of nebivolol generally ranges from 7 to 10 hours. 
Contraindications 
• Bronchial asthma or related bronchospastic conditions.  
• Second- or third-degree AV block 
• Sick sinus syndrome 
• Severe bradycardia (unless a permanent pacemaker is in place) 
• Patients with cardiogenic shock or who have decompensated heart failure 
requiring the use of intravenous inotropic therapy. 
• Patients with severe hepatic impairment 
• Patients with a history of a serious hypersensitivity reaction (e.g., Stevens-
Johnson syndrome, anaphylactic reaction, angioedema). 
Therapeutic indications: Nebivolol can be used in the following indications: 
• Hypertension  
• Congestive heart failure 
• Myocardial infarction 
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Marketed dosage forms: 
Bystolic controlled release tablets of nebivolol in doses 2.5mg, 5mg, 10mg, 
20mg.  
5.2 EXCIPIENT PROFILE: 
CROS POVIDONE67 
Synonyms : Crosslinked povidone ;EI 202;Kollidon CL;Kollidon CL- 
  M;polyplasdon XL 10 ; Polyvinyl poly pyrrolidone ;PVPP; 
  1-vinyl -2-pyrrolidone homopolymer. 
Description :  Crospovidone is a white to creamy white finely devided, free  
  flowing practically tasteless, odourless or nearly odourless  
  hygroscopic powder. 
Chemical name : 1-ethenyl -2 –pyrrolidone homopolymer. 
Molecular weight : >1000000 
Functional category: Tablet disintegrant (Raymond C.Rowe et al, 2001) 
Applications in Pharmaceutical Formulation 
 Cropovidone is a water –insoluble tablet disintegrant and dissolution agent 
used at 2-5% concentration in tablet prepared by direct compression method (1-6). It 
rapidly exibit high capillary activity and pronounced hydration capacity, with little 
tendency to form gels. Studies suggest that the particle size of crospovidone strongly 
influences disintegration of analgesic tablets  
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SODIUM STARCH GLYCOLATE68 
Synonyms : Primojel; Starch carboxy Methyl ether, sodium salt, Tablo; 
Description  : Tasteless, free flowing powder. The Ph Eur 2005 states that  
  it consist of oval or spherical granules, 30-100 um in 
  diameter, with some less spherical granules ranging from 
  10-35um in diameter. 
Chemical name:  Sodium carboxy methyl starch. 
Molecular weight  : 5 X 10 5 -1 
Functional category : Tablet and capsule disintegrant. 
Applications in Pharmaceutical Formulation  
 Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. It is commonly used in tablets 
prepared by either direct compression or wet granulation process. The usual 
concentration employed in a formulation is between 2% and 8% with the optimum 
concentration about 4% although in many cases 2% is sufficient. Disintegration 
occurs by rapid uptake of water followed by rapid and enormous swelling. 
 Although the effectiveness of many disintegrant is affected both presence of 
hydrophobic excipients such as lubricant the disintegrant efficiency of sodium starch 
glycolate is unimpaired increasing the tablet compression pressure also appears to 
have no effect on disintegration time. Sodium starch glycolate has also been 
investigated for use as a suspending vehicle.  
Chapter 5  Profiles 
Dept. of Pharmaceutics  36 J.K.K. Nattraja College of Pharmacy 
CARBOXY METHYL CELLULOSE CALCIUM 69 
Synonyms : Calcium CMC ; ECG 505 ; Nymcel ZSC ; Calcium  
   Carboxy methyl cellulose 
Description : It occurs as a white to yellowish- white hygroscopic fine 
   powder 
Chemical name : Cellulose, carboxy methyl ether, calcium salt 
Functional category : Stabilizing agent, suspending agent, tablet and capsule 
   disintegrant; tablet binder; viscosity increasing agent  
   Water Abosrbing agent. 
Application in Pharmaceutical Formulation 
 It used as binder, diluents and disintegrant. It is an effective disintegrant as it 
swells to several times it’s original bulk on condact with water. Concentration up to 
15 % w/w may be used in tablet formulations; above this concentration, tablet 
hardness is reduced. 
 It is also used as suspending or viscosity increasing agent in oral and topical 
formulations. And also used in modern wound dressings for it’s water absorption, 
retension and hemostatic properties. 
SODIUM STEARYL FUMERATE70 
Synonyms : Fumeric acid, Otadecyl ester sodium salt; Pruv ; Sodium  
   monosrearyl fumerate. 
Description : Sodium stearyl fumerate is a fine white powder with  
   agglomerates of flat, circular shaped particles. 
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Chemical name : 2-butenedioic acid, monooctadecyl ester, sodium salt 
Molecular weight  : 390.5 
Functional category : Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation 
 Sodium stearyl fumerate is used as lubricant, in capsule and tablet 
formulations at 0.5 – 2.0 % w/w concentration. It is also used in certain food 
applications conditioning or stabilizing agent in various backery Products, flour-
thickened foods, dehydrated potatos and processed cereal up to 0.2-1.0 % by weight 
of the food. 
TALC 71 
Synonyms : Atalc ; E 55 3 b; hydrous magnesium calcium silicate ;  
   hydrous magnesium Silicate; magnesium hydrogen  
   metasilicate ; Magsil osmanthus; magsil star; powdered 
   talc; purified French chalk; Purtalc ; soapstone; steatite;  
   superior 
Description : Talc is very fine to grayish –white, odorless, impalatable,  
   unctuous, crystalline powder. It adheres readily to the skin  
   and is soft to touch and free from grittiness. 
Chemical name :  Talc 
Functional category  : Anticaking agent; glidant; tablet and capsule diluents;  
   tablet and capsule lubricant. 
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Applications in pharmaceutical formulation 
 Talc was once widely used in oral solid dosage formulations as a lubricant 
and diluent although today It is less commonly used. It is widely used as dissolution 
retardant in the development of controlled release product. Talc is used as a lubricant 
in tablet formulations; in novel powder coating for extended-release pellets; and as 
an adsorbent. 
In topical preparations, talc is used as a dusting powder, although it should 
not be used to dust. Surgical gloves. As it is a natural material it may contain 
microorganisms and should be sterilized when used as dusting powder. Talc used to 
clarify liquids and is also used in cosmetics and food products, mainly for it’s 
lubricant properties 
POLYETHYLENE GLYCOL 600072 
Synonyms: 
 Breox peg; carbowax; hodag peg; lutrol E; PEG: polyethylene glycol. 
Chemical Name and CAS registry number: 
 ά-hydro-ω- hydro- poly (oxy-1, 2- ethane diyl) and [25322-68-3] 
Molecular weight: 
 5000 – 7000 (average molecular weight) 
Description: 
Polyethylene glycol grades 6000 and above are available as free-flowing 
milled powders, colorless or slightly yellow colured. They have a slight, but 
characteristic odour and a bitter, slightly burning taste. 
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Typical properties: 
1) Density; 1.15–1.21 g/cm3 at 25°C. 
2) Melting Point: 55–63°C 
3) pH (5% w/v solution): 4.0-7.0. 
4) Hydroxyl value: 16–22. 
Incompatibilities: 
All grades can exhibit some oxidizing activity due to the presence of 
peroxide impurities and some secondary product formed by auto- oxidation. Solid 
polyethylene glycols grades may be incompatible with some colour. 
Safety: 
 Nontoxic and non-irritant material, when administered topically may cause 
stringing. 
Application in pharmaceutical formulation: 
Polyethylene glycols can also be used to enhance the aqueous solubility or 
dissolution characteristics of poorly soluble compounds by making solid dispersions 
with an appropriate polyethylene glycol. Animal studies have also been performed 
using polyethylene glycols as solvents for steroids in osmotic pumps. 
MICROCRYSTALLINE CELLULOSE73 
Nonproprietary Names: 
• BP: Microcrystalline cellulose 
• JP: Microcrystalline cellulose 
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• PhEur: Cellulosum microcristallinum
• USPNF: Microcrystalline cellulose
Synonyms:  
Cellulose gel;; crystalline cellulose; E460;; Fibrocel;; Tabulose.
Chemical Name and CAS Registry Number:
Cellulose [9004
Empirical Formula and Molecular Weight:
(C6H10O5)n ≈36
where n ≈ 220.
Structural Formula: 
Functional Category:
Adsorbent; suspending agent; tablet and capsule diluents;
Applications in Pharmaceutical Formulation or Technology:
Microcrystalline cellulose is widely used in pharmaceuti
binder/diluents in oral tablet and capsule formulations where it is used in both wet
granulation and direct
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binder/diluents (20–90%), microcrystalline cellulose also has some lubricant and 
disintegrant (5–15%) properties that make it useful in tableting. 
Description: 
Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications. 
Density (bulk) 
• 0.337 g/cm3; 
• 0.32 g/cm3 for Avicel PH-101; 0.29 g/cm3 for Emcocel 90M; 0.29 g/cm3 for 
VivaPur 101. 
Density (tapped) : 
• 0.478 g/cm3; 
• 0.45 g/cm3 for Avicel PH-101; 
• 0.35 g/cm3 for Emcocel 90M.  
Density (true) : 
• 1.512–1.668 g/cm3 
Melting point: 
Chars at 260–270°C. 
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Solubility: 
Slightly soluble in 5 % w/v sodium hydroxide solution; practically insoluble 
in water, dilute acids, and most organic solvents. 
Stability and Storage Conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
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6. MATERIALS AND METHODS 
MATERIALS74 
Table No 3: Materials used and their suppliers 
 MATERIALS  SUPPLIERS 
Nebivolol Zydus pharma,Hosur 
Ispagol Gujarath International, Gujarath.  
PEG 6000 Micro lab, Mumbai. 
Microcrystalline cellulose Loba chemi, Mumbai 
Sodium starch glycolate Research lab fine chem., Mumbai 
Cros povidone Reasearch lab fine chem., Mumbai 
Sodium alginate Loba chemi, Mumbai. 
Talc Lobachemi, Mumbai. 
Aspartame Bangalore antibiotics & Biological, Salam. 
Aerosil Lobachemi, Mumbai. 
Methanol Himedia lab, Mumbai. 
Hcl Micro Lab, Mumbai. 
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METHODS 
Table No. 4. Process equipments and their suppliers 
EQUIPMENTS SUPPLIERS 
Electronic balance Shimadzu weighing balance 
Magnetic stirrer Remi equipments  
Hot air oven In lab equipments , Chennai. 
Orbit shaker Lab India. 
Proton mini press tablet punching 
machine 
Proton 
Hardness tester Tab machines 
Friability tester Roche Friabilator 
Vernier caliper Mituyoko Japan 
Dissolution Apparatus Lab India Disso 2000 
UV visible spectrophotometer Lab India  
FT IR Spectrometer Brukle alpha 
Disintegration apparatus Rolex 
 
6.1 PRE-FORMULATION STUDIES:75 
Preformulation may be described as a phase of the research and development 
process where the formulation scientist characterizes the physical, chemical and 
mechanical properties of new drug substances, in order to develop stable, safe and 
effective dosage forms.  
6.1.1 Organoleptic properties: 
Appearance 
Transferred approximately 2gm of the sample on a white paper spreaded 
uniformly and examined visually. 
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Colour: a small quantity of pure nebivolol powder was taken in a butter paper and 
viewed in well illuminated place. 
Taste and odour: very less quantity of nebivolol was used to get taste with the help 
of tongue as well as smelled to get the odour. 
6.1.2 Loss on drying:  
Determine on 1 g by drying in an oven at 100°C to 105°C for 3 hours. Mixed 
and accurately weighed the substance to be tested. Tare a glass stopper, shallow 
weighing bottle that has been dried for 30 minutes under the same conditions to be 
employed in the determination. Weighed the empty bottle (W1). Put the sample in 
bottle, replace the cover, and accurately weighed the empty bottle with contents 
(W2). By gentle, sidewise shaking, distributed the sample as evenly as practicable to 
a depth of about 5 mm. Placed the loaded bottle in the drying chamber. Dried the 
sample at the specified temperature in desicator before weighing. Weighed the bottle 
(W3).The difference between successive weights should not less than 0.3%. 
The loss on drying is calculated by the formula: 
                            (W2-W3) 
% LOD = ----------------------------- X 100 
                            (W2-W1) 
 Where, W1 = Weight of empty weighing bottle 
  W2 = Weight of weighing bottle + sample 
 W3 = Weight of weighing bottle + dried sample 
  
Chapter 6  Materials and Methods 
Dept. of Pharmaceutics  46 J.K.K. Nattraja College of Pharmacy 
6.1.3 Angle of repose:  
Angle of repose is the maximum angle of a stable slope determined by 
friction, cohesion and the shapes of the particles. The internal angle between the 
surface of the pile and horizontal surface is known as the angle of repose and is 
related to the density, surface area and co-efficient of friction of the raw material. 
Method: Angle of repose was determined by using funnel method. The 
height of the funnel was adjusted in such a way that the tip of the funnel just touches 
the heap of the blends. Accurately weighed blend is allowed to pass through the 
funnel freely on the surface. The height and diameter of the powder cone was 
measured and angle of repose was calculated using the following equation. 
Ө = tan-1 (h/r) 
Where, h = height of heap, r = radius of heap, Ө = angle of repose. 
Table-5: Limits: 
Angle of repose Flow property 
<25o Excellent 
25-30 o Good 
30-40 o Passable 
>40 o Very poor 
 
 
6.1.4 DETERMINATION OF DENSITIES; 
Bulk density: Bulk density is defined as the mass of the powder divided by 
the bulk volume. Bulk density largely depends on particle shape, as the particle 
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become more spherical in shape, bulk density was increased. In addition as the 
granule size increases bulk density decreases. 
Method: A quantity of 5 gm of powder weighed and transferred to a 
measuring cylinder and observed the volume occupied by the sample. The initial 
volume was calculated. Bulk density was calculated using the formula. 
Bulk Density = Bulk Mass / Bulk Volume 
Tapped density: Tapped density is achieved by mechanically tapping a 
measuring cylinder containing a powder sample. After observing the initial volume, 
the cylinder is mechanically tapped and volume readings are taken until little further 
volume changes is observed the mechanical tapping is achieved by raising the 
cylinder and allowing it to drop under its own weigh a specific distance. Device that 
rotates device during tapping may be preferred to minimize any possible separation 
of the mass during tapping down. 
  The powder in the measuring cylinder were tapped for specific times at a 
height of 2.5 cm at a interval of 2 seconds. The powder in the graduated cylinder 
were tapped for specific times at a height of 2.5 cm at an interval of 2 seconds. The 
final volume occupied by the sample was noted and tapped density was calculated 
by using the formula: 
Tapped Density = 
Vf
m
 
  Where, m = initial weight of material in gm, Vf = volume of material after 
tapping.  Generally replicate determinations are desirable for the determination of 
this property. 
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6.1.5 Measurement of Powder Compressibility: 
  Based on the apparent bulk and the tapped density, the percentage 
compressibility of bulk was determined by the following formula.  
Compressibilityindex: = 
0
0 )(100
V
VfV −
 
Where, Vf = final tapped volume, Vo = initial un tapped volume 
Table – 6 : Limits: 
S. No. Compressiility index Flow 
1 5-12 Free flow 
2 12-16 Good flow 
3 18-21 Fair 
4 23-25 Poor 
5 33-38 Verypoor 
6 >40 Extremely poor 
 
HausnerRatio: = 
Vf
V0
 
Where, Vf = final tapped volume, Vo = initial un tapped volume. 
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Table - 7: Limits: 
S.No Hausner’ ratio Flow 
1 1-1.2 Free flowing 
2 1.2-1.6 Cohesive powder 
 
6.1.6 Solubility analysis: 
Solubility is important pre-formulation parameter because it affects the 
dissolution of drug, bio availability of drug. 
 Method: solubility of nebivolol was determined in methanol, ethanol, 
dimethyl fluoride methylchloride,0.1NHCl.solubility studies were performed by 
taking excess amount of nebivolol in different beakers containing the solvent. The 
mixture was shaken for 10hrs at regular intervals .the solution was filtered by using 
whatmann filter paper. The filtered solution were analysed spectrophotometrically. 
61.7. PH  
 Weighed and transferred accurately about 1.0 g of sample in 20 ml clean and 
dried volumetric flask dissolved in carbon dioxide free water and made up the 
volume to 20 ml with the same solvent, mixed. Determined the pH of freshly 
prepared solution by using recalibrated pH meter. 
6.1.8 ASSAY  
 Weighed accurately 10mg of nebivolol sample and added to 100 ml 
volumetric flask. Added 1ml of methanol mixed for 10 minutes added 70ml of 0.1 N 
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Hydrochloric acid and dissolved it.Make up the volume to 100ml with 0.1 N 
Hydrochloric acid.Took 10ml and diluted to 100ml with 0.1 N HCL.Took 1ml and 
diluted to 10 ml with 0.1 N HCL, absorbance measured at 282nm. 
6.2. DRUG-EXCIPIENT COMPATIBILITY STUDY BY FTIR 
 Infra Red spectroscopy is one of the most widely used tools for purity 
analysis of drugs in pharmaceutical industry. Fourier Transform IR spectra were 
recording using Brukle alpha spectrometer. KBr powder was to prepare used to 
prepare pellet for sampling. The scanning range was 4000-400cm. 
6.3 PREPARATION OF STANDARD CURVE 
The calibration curve is based on the spectrophotometry. The maximum 
absorption was observed at 282nm. It obeyed Beer’s law in the concentration range 
of 10-50 µg/mL. 
Preparation of stock and standard solution:  
The standard solution of nebivolol hydrochloride was prepared by accurately 
weighing 10 mg of the drug. It was diluted in a 100 mL volumetric flask with 
methanol to give a range of solutions with final concentrations of 5–50 mg/mL. The 
absorbance of each solution was determined at 282 nm. 
Preparation of various concentrations: 
10 ml stock solution was taken from stock solution-2 and volume made up to 
100 ml by using 0.1 N HCl to get 100 µg/ml concentrations. From this solution 10-
50 µg/ml concentrations were prepared. 
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6.4. Preparation of solid dispersion and physical mixture76; 
6.4.1. Solid dispersions prepared by melting the carrier  
Solid dispersions (SDs) preparations containing different weight ratios of 
nebivolol in PEG6000 (1:1, 1:2, 1:5) were prepared by the melting method. 
Nebivolol was added to the melted PEG 6000 at 75oC and the resulting homogenous 
preparation was rapidly cooled in a freezing mixture of ice and sodium chloride, and 
stored in desiccators for 24h.Subsequently, the dispersion was ground in a mortar 
and sieved through 50#. 
6.4.2. Physical Mixture 
Physical mixture (PMs) having the same weight ratios were prepared by 
thoroughly mixing appropriate amounts of nebivolol and PEG 6000 in a mortar until 
a homogenous mixture was obtained. The resulting mixture were sieved through a 
50# sieve and denoted as PM. 
6.5. Characterization of solid dispersions of nebivolol with PEG 600077 
6.5.1. Drug content  
The drug content in each solid dispersion and physical mixture was 
determined by the UV-spectroscopic method. An accurately weighed quantity of 
solid dispersion or physical mixture, equivalent to 40 mg of nebivolol, was 
transferred to a 100-mL volumetric flask containing 10ml of methanol and 
dissolved. The volume was made up to 100ml with 0.1 N HCL. The solution was 
filtered through 0.45-mm membrane filter paper. One ml of this solution was diluted 
100 times with 0.1 N HCL to achieve 6 µmol L–1 and the absorbance was measured 
at 282 nm. 
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6.5.2. Phase-Solubility Study 
Phase-solubility studies were carried out by adding excess of drug (20 mg) in 
screw-capped vials containing 20ml of aqueous solution of different PEG 6000 
concentration. The suspensions were continuously stirred on electromagnetic stirrer 
at 250 and 370C and 300 rpm for three days (this duration was previously tested to be 
sufficient to reach equilibrium). The suspensions were filtered through 0.22µm 
membrane filter. The filtrate were suitably diluted and analyzed, 
spectrophotometrically, for the dissolved drug at 282nm. 
6.5.3. Dissolution Studies: 
Dissolution studies of nebivolol in powder form, SDs, and PMs were 
performed by using the USP type II paddle apparatus at the paddle rotation speed of 
50 rpm in 900ml of 0.1 N HCl as a dissolution medium at 37±0.5 °C. The SDs or 
PMs equivalent to 10 mg of nebivolol were weighed using a digital balance and 
added into the dissolution medium. At the specified times (every 10 min for 2 
hours), 10ml samples were withdrawn by using syringe filter (0.45 µm) and then 
assayed for nebivolol content by measuring the absorbance at 282 nm using a UV-
Visible spectrophotometer . Fresh medium (10ml), which was prewarmed at 37 °C, 
was added to the dissolution medium after each sampling to maintain its constant 
volume throughout the test.  
6.5.4. Fourier transforms IR spectroscopy: 
Fourier-transform infrared (FT-IR) spectra were obtained by using Bruker 
Alpha FTIR. The samples (nebivolol or SDs or PMs) were previously ground and 
mixed thoroughly with potassium bromide, an infrared transparent matrix, at 1:5 
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(Sample/KBr) ratio, respectively. The KBr discs were prepared by compressing the 
powders at a pressure of 5 tons for 5 min in a hydraulic press.  
6.6 PREPARATION OF NATURAL SUPERDISINTEGRANTS (PLANTAGO 
OVATA SEED POWDER, MUCILAGE AND HUSK POWDER)78: 
 The powder of seeds and husk were prepared by an automatic grinder and 
sieved (#80). Then it stored in a desicator until use .For isolation of seed mucilage, 
the cleaned seeds of Plantago ovate were soaked in distilled water 48 hrs and then 
boiled few minutes so that mucilage was completely released in to water. This 
material squeezed through muslin cloth for filtering and separating out the marc. 
Then an equal volume of acetone was added to the filtrate so as to precipitate the 
mucilage .The mucilage was dried in oven (less than 60 oC), powdered, sieved (# 80) 
and stored in desicator until use. 
 The natural super disintegrants were evaluated for their physicochemical 
properties. The swelling index is calculated, it is the volume in milliliters that is 
occupied by 1g of drug or any substance after it has swollen in an aqueous liquid for 
4 hr. The physical mixture of drug complex with this super disintegrants was 
allowed to stand for 7 days and the assay of drug was performed for compatability 
studies.  
 Preparation of the prepared natural super disintegrants were evaluvated for 
swelling factor, bulk density, tapped density, angle of repose. Angle of repose were 
calculated according to the formula procedure in 6.1.4 Bulk density and tapped 
density were found out using the procedure given Compressibility and Hausner’s 
ratio were found out according to the formula 6.1.4. 
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6.7. FORMULATION OF IMMEDIATE RELEASE TABLETS OF 
NEBIVOLOL.79 
 Different Nebivolol Immediate Release Tablets were prepared according to 
the proportions given in the table no 9. The raw materials passed through a screen (# 
60). Prior to mixing powdered separately the Nebivolol Solid dispersion, and 
weighed the amount equivalent to 10 mg Nebivolol, was mixed with other excipents 
and compressed proton miniplus tablet punching machine. The tablet weight was 
adjusted to 430 mg. All formulation prepared according to the following formulation 
table.  
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Table No. 8 - FORMULATION OF IMMEDIATE RELEASE TABLET 
INGREDIENTS Quantity in mg per tablets 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1:5 Solid dispersion 
equivalent to 40 mg Nebivolol 
240 240 240 240 240 240 240 240 240 240 240 240 
MCC 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0 
Mannitol 79.0 76.0 79.0 76.0 79.0 76.0 79.0 76.0 79.0 76.0 79.0 76.0 
Isphagol mucilage 9.0 12.0 - - - - - - - - - - 
Isphagol powder    9.0 12.0         
Isphagol husk Powder - - - - 9.0 12.0 - - - - - - 
Cross povidone - - - - - - 9.0 12.0     
SSG - - - - - - - - 9.0 12.0   
Calcium CMC - - - - - - - - - -- 9.0 12.0 
SSF 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Talc 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
Aerosil 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 
Aspartame 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Orange flavor 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 
Total weight (mg ) 430 430 430 430 430 430 430 430 430 430 430 430 
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6.8 Evaluation of Immediate Release Tablet: 
6.8.1. PHYSICAL APPEARANCE 
 Prepared Oral Disintegrating Tablets were evaluated for the smoothness and 
absence of cracks, chips and other undesirable characteristics. 
6.8.2 WEIGHT VARIATION 
 Twenty tablets were randomly selected and weighed to determine the average 
weight and were compared with individual tablet weight. The percentage weight 
variation was calculated. As per Indian Pharmacopoeia specification, tablet with an 
average weight weight between 80 – 250 mg, percentage deviation should not more 
than ±
 
7.5 % and the tablet with an average weight more than 250 mg should not be 
more than ± 10 %. 
                              Tablet weight – Average weight 
% Deviation =                                                                 X 100  
                                             Tablet weight 
6.8.3. FRIABILITY 
 Friability of the tablets was checked by Roche friabilator. In this device, 
tablets subjected to combined effects of abration and shock by utilizing a plastic 
chamber that revolves at 25 rpm, dropping the tablets at a distance of 6 inches in 
each revolution. Pre weighed tablets were placed in friabilator, which was then 
operated for 100 revolutions. The tablets were dusted and reweighed. 
                                     W0 – W  
 F =                                                       X 100  
                                         W  
W0 = initial weight, W =final weight. 
Chapter 6  Materials and Methods 
Dept. of Pharmaceutics  57 J.K.K. Nattraja College of Pharmacy 
6.8.4. THICKNESS 
 The thickness were measured using vernier caliper and values were tabulated. 
Three tablets of each batch were measured. Average and standard deviation was 
calculated.  
6.8.5. HARDNESS 
 Monsanto hardness tester was used for the determination of hardness. For 
each formulation 3 tablets were determined.  
6.8.6. DISINTEGRATION TIME 
 Disintegration time of 6 tablets from each formulation was determined by 
using USP disintegration apparatus. Disintegration test was carried out in 900 ml 
buffer pH 6.8 at 37 ± 2 0C and apparatus operated for 3 minutes, six tablets were 
taken and one tablet was introduced in each tube, disc was placed and basket and the 
disintegration time in seconds was noted.  
6.8.7. WETTING TIME 
 This is carried out as a measure of hydrophilicity of tablets. Wetting time is a 
length of time required to wet the tablet. A piece of tissue paper (12 x 10.75) was 
folded twice was placed in the small Petri dish (I.D 6.5cm ) containing 6 ml of buffer 
pH 6.8 simulated to salivary pH , tablet was placed on the paper and time for 
complete wetting was measured. Three trials of each batch were performed and 
standard deviation was determined. 
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6.8.8. UNIFORMITY OF DISPERSION TEST 
 Two tables from each batch were separately kept in 100 ml water and gently 
tirred for 2 minutes. The dispersion was passed through 22 mesh. The tablet were 
considered to pass the test if no residue remained on the screen.  
6.8.9. WATER ABSORPTION RATIO 
 Water absorption ratio, which is important criteria for understanding the 
capacity of disintegrants to swell in the presence of little amount of water. Weight of 
the tablet after and before the test was taken. Water absorption ratio (R) is calculated 
using following formula.  
                                       Wa – Wb  
  R = X 100 
                                           Wb  
Where,  
Wa = weights of the tablets after water absorption test 
Wb = weight of the tablets before water absorption test 
6.8.10. ASSAY 
STANDARD PREPARATION  
 Weighed accurately 50 mg of Nebivolol and added to 100 ml volumetric 
flask, dissolved in minimum quantity of methanol. The volume made up to 100 ml 
with 0.1 N hydrochloric acid. Took 10 ml of that solution and diluted to 100 ml with 
0.1 N hydrochloric acid. Took 1 ml from that solution and diluted to 10 ml with 0.1 
N hydrochloric acid.  
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SAMPLE PREPARATION 
 Crushed 15 tablets and weighed quantity equivalent to 50 mg Nebivolol , 
dissolved in minimum quantity of methanol 0.1 N hydrochloric acid mixed well and 
volume made up to 100ml. Filtered the solution and 10 ml of this solution diluted to 
100 ml. From that took 1ml and diluted to 10 ml .Absorbance measured at 282 nm 
by UV/Visible spectrophotometer.  
 
6.8.11. DISSOLUTION STUDIES 
 Dissolution studies were carried out using USP type II (paddle apparatus) at 
50 rpm 0.1 N Hydrochloric acid was used as dissolution medium. Temperature was 
maintained at 37 ±0.5 0C. Aliquots of dissolution media was withdrawn at specific 
time intervals and it was filtered. Same quantity of fresh media was replaced. The 
filtered solution was used to determine the estimation of drug content. The 
absorbance were measured at 282 nm by UV/Visible spectophtometer. The test was 
carried out for 30 minutes. 
6.8.12. Kinetic Study 
 The release data obtained from optimized formulation was studied further for 
the fitness of data in different kinetic models like, zero order,  first order, Higuchi’s 
and KORSMEYER – Peppa’s. 
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6.9. ACCELERATED STABILITY STUDIES 
 Selected formulation were subjected to stability studies as per I.C.H 
guidelines. Following conditions were used for stability testing. 40 0 C / 75 % RH 
analyzed every month for a period of two months as per I.C.H guidelines. By 
keeping 40 ± 20C /RH the formula analyzed every month for a period of 3 months. 
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7. RESULTS AND DISCUSSION 
7.1. Preformulation Studies  
7.1.1. Organlopetic Properties  
These tests were performed as per procedure given in 6.1.1. The results were 
illustrated in table no. 9.  
Table No. 9: Organoleptic Properties 
Test Specification/Limits Observations 
Color White or almost white powder White powder 
Odour Odourless Odourless 
 
7.1.2. Loss on Drying  
This test was done as per procedure stated in 6.1.2. The result were 
illustrated in table no. 10.  
Table No.10 : Loss on Drying 
Test  Specification/Limits Observations 
Loss on drying  Not more than 0.5% 0.087% 
 
7.1.3. Flow Properties (Angle of repose) 
 It was determined as per procedure given in 6.1.3. The results were 
illustrated in tables No. 11.  
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Table No.11: Flow properties  
Material Angle of repose 
Nebivolol 28o.80” 
 
*Average of three determinations 
7.1.4 Determination of Density 
It was determined as per procedure given in 6.1.4. The results were 
illustrated in table no. 12. 
Table No.12: Density 
Material Bulk Density (gm/ml) Tapped density (gm/ml) 
Nebivolol 0.21 0.31 
 
*Average of three determinations 
7.1.5. Powder compressibility  
It was determined as per procedure given in 6.1.5. The results were 
illustrated in table no. 13.  
Table No.13: Powder Compressibility  
Materials Compressibility index Hausner ratio 
Nebivolol  15.23% 1.34% 
 
*Average of three determinations 
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7.1.6. Solubility  
It was determined as per procedure given in 6.1.6. The results were 
illustrated in table no. 14.  
Table No.14: Solubility 
Test Specification Result 
Solubility in water, Methanol, 
Methylene chloride, alcohol. 
Practically insoluble in water, freely 
soluble in methylene chloride, 
slightly soluble in ethanol. 
 
Complies 
 
7.1.7 pH of the solutions  
pH of the solution was determined as per procedure given in 6.1.7. The 
results were illustrated in table no. 15.  
Table No.15: pH 
Test  Specification  Observation  
pH 2.5 2.4 
 
7.1.8. Assay  
It was determined as per procedure given in 6.1.8. The results were 
illustrated in table no. 16.   
Table No.16: Assay 
Test  Specification  Observation  
Assay  90 - 110.0 % 98.81%  
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7.2. DRUG EXCIPIENTS COMPATABILITY STUDY BY FTIR;
 Compatability study was perfomed using FT
spectrum of pure drug,physical mixture of drug and excipients were studied by 
making a KBr pellet. 
The spectral details for the drug and physical mixtures are shown as follows
 Table No. 17: FT-IR Peak Of Various Components.
Characteristic bands
N-H 
C=O 
C-F 
 Results and Discussion
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-IR spectrophotometer .The IR 
 
 Pure drug Physical mixture
2905.89cm-¹ 3000.14cm
1710.74cm-¹ 1735.04cm
1350.08cm-¹ 1375.65cm
 
Fig. No. 1: IR spectrum of nebivolol 
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-¹ 
-¹ 
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Fig. No. 2: Ispagol Mucilage 
 
 
Fig. No. 3: Ispagol Seed Powder 
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Fig. No. 4: Ispagol Husk Powder 
 
 
Fig. No. 5: IR Spectra of Microcrystalline Cellulose 
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Fig. No. 6: IR Spectra of Crospovidone 
 
Fig. No. 7: IR Spectra of Croscarmellose Sodium 
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Fig. No. 8: IR Spectra of Sodium Starch Glycolate 
 
Fig. No. 9: IR Spectra of PEG 6000 
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Fig. No. 10: IR Spectra of Nebivolol & Excipient Mixture 
 
The FT-IR Spectra analysis showed that there is change in percent 
transmittance which may be due to change in crystallinity and there is no 
appearance or disappearance of any characteristics peak of pure drug nebivolol and 
in the physical mixture of drug to polymer, which confirms the absence of chemical 
interaction between drug and polymer. 
7.3. PREPARATION OF STANDARD CURVE 
 A UV spectrophometric method given in IP is used for dissolution samples of 
nebivolol tablet. Absorbance scans of drug in 0.1N HCL, showed maximum at 282 
nm, which is selected as the analytical wavelength. Standard curve of nebivolol in 
0.1N HCL. Calibration curve of nebivololl was determined by plotting absorbance 
(nm) versus concentration (µg/ml) at 282 nm. The results obtained are as follows. 
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Table – 18: Standard curve of nebivolol 
Concentration Absorbance 
10 0.123 
20 0.280 
30 0.436 
40 0.654 
50 0.812 
 
The linear regression analysis was done on absorbance data points. A straight 
line generated to facilitate the calculation of amount of drug, the equation is as follows: 
Y = mx + c 
Where Y=absorbance, m=slope, x=concentration 
 
Fig. 11 : Standard plot for nevibolol in 0.1N HCL 
7.4. PREPARATION OF SOLID DISPERSION AND PHYSICAL MIXTURE  
 As per the method given in 6.4.1 and 6.4.2 solid dispersion and physical 
mixture were prepared.  
0
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7.5. Characterization of solid dispersions of Nebivolol with PEG 6000 
7.5.1. Drug content 
It was determined as per procedure given in 6.5.1. The results were 
illustrated in table no. 19.  
Table No. 19: Drug content in physical mixtures and solid dispersions 
Solid dispersion 
(drug to PEG mass 
ratio) 
Drug content 
(%) 
Physical mixture 
(drug to PEG mass 
ratio) 
Drug content 
(%) 
SD 1:1 99.25 PM 1:1 96.61 
SD 1:2 98.47 PM 1:2 97.98 
SD 1:5 99.71 PM 1:5 99.11 
 
7.5.2. Phase solubility Study 
It was determined as per procedure given in 6.5.2. The results were 
illustrated below. 
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Fig. 12: Solubility diagram of Nebivolol in presence of PEG 6000  
Fig no.12 represented the effect of different polymers concentration at 
different temperature on the solubility of Nebivolol. The plots of drug solubility 
against the polymer concentration at the investigated temperatures indicated a linear 
relationship between drug solution and polymer concentration. The result shown 
that in both cases, the solubility of Nebivolol increased with increasing temperature 
and carrier concentration. 
 Solubility of Nebivolol in pure water at 25oC was 0.01 mg/ml. At the highest 
polymer concentration (10% w/w), the solubility increased approximately 4 fold for 
PEG 6000 at 25o. The same tendency was observed for other temperatures. 
7.5.3. Dissolution studies 
It was determined as per procedure given in 6.5.3. The results were 
illustrated in table no. 20.  
Table No. 20: In-vitro Dissolution Profile of Nebivolol, Physical Mixture of 
Nebivolol and Solid Dispersion of Nebivolol in pH 1.2 Buffers. 
Sr. No. Formulations Percentage drug released after 30 minutes (DR) 
A1 Drug 38.23 ± 2.15 % 
A2 PM 1:1 42.54 ± 2.78 % 
A3 PM 1:2 45.86 ± 2.49% 
A4 PM 1:5 52.12 ± 2.70% 
A5 SD 1;1 88.89 ± 2.15 % 
A6 SD 1:2 94.46 ± 2.45 % 
A7 SD 1:5 99.35 ± 2.86 % 
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Fig. 13: Comparison of in-vitro dissolution profile of formulation A1-A7 
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The percentage release of Nebivolol at various time intervals from the 
physical mixtures and solid dispersions made by using various concentrations of 
PEG 6000 are shown in Fig.no.11. From table no.20 it is evident that onset of 
dissolution of pure Nebivolol is very low, about 38.24% of drug being dissolved 
within 30 min. In the 30 minutes, physical mixtures of PEG 6000 (1:1, 1:2 and 1:5) 
showed 42.54, 45.86 and 52.12% drug release, and 88.89, 94.46, and 99.35 % drug 
release from solid dispersions (1:1, 1:2 and 1:5). SDs of Nebivolol with PEG 6000 
considerably enhanced dissolution rates within 30 min compared to pure Nebivolol 
and PMs. 
7.5.4. Fourier transforms IR spectroscopy 
It was determined as per procedure given in 6.5.4. The following figures 
were illustrated results.  
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Fig. No. 14: IR Spectra of Solid dispersion 1:1 
 
 
Fig. No. 15: IR Spectra of Physical mixture 1:1 
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Fig. No. 16: IR Spectra of Solid dispersion 1:2 
 
Fig. No. 17: IR Spectra of Physical mixture 1:2 
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Fig. No. 18: IR Spectra of Solid dispersion 1:5 
 
Fig. No. 19: IR Spectra of Physical mixture 1:5 
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The IR spectra of SDs and PMs were compared with the standard spectrum 
of Nebivolol. IR spectrum of Nebivolol was characterized by the absorption of 
carbonyl (C=O) sulphonyl urea group at 1,706 cm−1. In spectra of SDs and PMs, 
this band was shifted towards higher frequencies at 1,725 and 1,711 cm−1 
respectively. Also the NH group which is located at 3,265 cm−1 from the IR 
spectrum of Nebivolol shifted to 3,365 cm−1 in SDs. The Flourine bands are located 
at 1,349 and 1,162 cm−1 in pure Nebivolol. In SDs, the asymmetric vibration peak 
of S=0 band was shifted from 1,349 to 1,341 cm−1 with decreased frequencies. It 
was concluded that there was no well defined chemical interaction between 
Nebivolol and PEG 6000 in SDs and in PMs, as no important new peaks could be 
observed.  
7.6. PREPARATION AND EVALUATION OF NATURAL 
SUPERDISINTEGRANTS 
 Natural super disintegrates were prepared and evaluated according to the 
procedure given in 6.6. 
Table No. 21 : Preliminary evaluation of natural superdisintegrants  
Parameters Mucilage Seed Powder Husk Powder 
Bulk Density (gm/cm3) 0.93 0.60 1.27 
Tapped Density (gm/Cm3) 1.02 0.81 1.45 
Hausners Ratio 1.063 1.24 1.21 
Compressibility index (%) 6.68 16.37 15.66 
Angle of Repose (o) 26.20 41.36 34.15 
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7.7. FORMULATION OF NEBIVOLOL IMMEDIATE RELEASE TABLET  
According to the formula given in table No. 8, Nebivolol immediate release tablet were formulated and before formulation 
precompression parameters were evaluated and given in table no. 22.  
 Table No : 22 Precompression parameters 
 
 
Parameters F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Bulk density 0.460 0.470 0.410 0.410 0.42 0.430 0.420 0.450 0.470 0.450 0.430 0.420 
Tapped Density 0.550 0.540 0.530 0.520 0.53 0.540 0.510 0.540 0.54 0.55 0.53 0.51 
% Compressibility 16.36 16.07 22.64 21.15 20.75 20.37 17.64 16.66 17.39 18.18 18.86 I7.64 
Hausners Ratio 1.195 1.14 1.29 1.26 1.26 1.25 1.21 1.40 1.14 1.22 1.33 1.21 
Angle of Repose 21.22 20.12 24.34 24.40 23.26 23.11 20.31 20.07 21.17 21.23 25.33 24.17 
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7.8. EVALUATION OF IMMEDIATE RELEASE TABLETS 
7.8.1. TABLET PHYSICAL APPEARANCE 
 The tablets were evaluated for their physical properties like color uniformity, 
presence of cracks, chipping, etc. No undesirable properties were found out. 
7.8.2. WEIGHT VARIATION TEST 
 It was determined as per procedure given in 6.8.2. The results were illustrated 
in table No. 23.  
7.8.3. FRIABILITY 
 The friability test were carried out according to the procedure given in 6.8.3. 
The result were tabulated in the Table No. 24. 
7.8.4. THICKNESS 
 The thickness were carried out according to the procedure given in 6.8.4. The 
result were tabulated in the table No.23. 
7.8.5. HARDNESS (KG/CM2) 
 The Hardness test were carried out according to the procedure given in 6.8.5. 
The result were tabulated in the table No.23. 
7.8.6. DISINTEGRATION TEST (IN SEC.) 
 It was determined as per procedure given in 6.8.6 the results were illustrated 
in table No.23. The results indicated that the disintegration time of tablets was within 
35seconds. 
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7.8.7. WETTING TIME 
 It was determined as per procedure given in 6.8.7 .The results were illustrated 
in table 23. 
7.8.8. TEST FOR UNIFORMITY OF DISPERSION 
 It was determined as per procedure given in 6.8.8. The results were illustrated 
in table No.23.  
7.8.9. WATER ABSORPTION RATIO 
 The test is conducted according to the procedure given in 6.8.9. To measure 
the hydrophilicity of tablets, the results were illustrated in the table No.23. 
7.8.10 ASSAY 
 It was determined according to the procedure given in 6.8.10. The percent 
purity was detrmined by UV method, the results were illustrated in the table No.23. 
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Table No.23: EVALUATION CHART OF TABLET 
Sr. 
No 
Para meter Formulation Code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1 Weight 
Variation Test 
428.61 
±0.26 
429.62 
±0.21 
428.66 
±0.36 
431.12 
±0.46 
430.14 
±0.26 
429.63 
±0.45 
431.15 
±0.36 
429.11 
±0.31 
431.52 
±0.26 
428.71 
±0.28 
428.26 
±0.26 
431.63 
±0.26 
3 % Friability 0.36 0.30 0.31 0.40 0.38 0.30 0.33 0.31 0.34 0.42 0.35 0.33 
4 Thickness (mm) 2.78± 
0.03 
2.79± 
0.02 
2.65± 
0.04 
2.60± 
0.03 
2.71± 
0.04 
2.72± 
0.03 
2.72± 
0.01 
2.78± 
0.05 
2.74± 
0.03 
2.73± 
0.04 
2.71± 
0.03 
2.65± 
0.04 
5 Hardness (Kg / 
cm2) 
3.54 
±0.12 
3.58 
±0.13 
3.98 
±0.21 
3.46 
±0.17 
3.18 
±0.15 
3.06 
±0.17 
3.24 
±0.2 
3.26 
±0.23 
3.03 
±0.19 
3.38 
±0.17 
3.14 
±0.21 
3.08 
±0.19 
6 Disintegration 
Time(sec) 
23.33 
±2.1 
21.00 
±1.5 
27.33 
±2.3 
23.66 
±2.0 
25.66 
±2.5 
26.00 
±3.0 
26.00 
±2.5 
24.66 
±2.1 
28.00 
±2.2 
26.66 
±3.1 
34.66 
±2.1 
34.66 
±2.2 
7 Wetting time 
(sec) 
50.66 
±1.9 
47.66 
±1.5 
63.00 
±2.3 
66.33 
±2.2 
63.33 
±2.0 
57.67 
±2.1 
54.33 
±1.9 
52.66 
±2.3 
52.00 
±2.2 
53.33 
±2.7 
65.33 
±2.6 
63.00 
±2.3 
8 Uniformity of 
Dispersion 
Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
9 W.A.Ratio (%) 65.41 65.38 73.87 74.01 66.02 67.37 65.32 65.31 66.17 66.98 74.12 73.65 
10 Assay(%) 99.2 99.8 98.6 98.4 98.2 98.7 98.6 99.7 99.8 99.9 99.9 98.4 
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7.8.11. IN-VITRO DISSOLUTION STUDIES 
  Dissolution study carried out according to procedure given in 6.8.11.The 
study or 30 minutes, the results were illustrated in the table below. 
Table No.24: Dissolution profile of formulation F1 
Time In Minute Cummulative Percent Drug Release(%) 
0 0 
5 67.81 
10 73.85 
15 79.47 
20 84.81 
25 91.82 
30 99.01 
 
Fig. No. 20. In-vitro dissolution study F1 
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Table No.25: Dissolution profile of formulation F2 
Time in 
minute 
Cummulative Percent 
Drug Release(%) 
0 0 
5 68.30 
10 74.06 
15 79.03 
20 85.16 
25 92.18 
30 99.93 
 
Fig. No. 21. In-vitro dissolution study F2 
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Table No.26: Dissolution profile of formulation F3 
Time in 
minute 
Percent Drug Release(%) 
0 0 
5 49.80 
10 53.82 
15 59.4 
20 64.89 
25 71.80 
30 79.00 
 
Fig. No. 22. In-vitro dissolution study F3 
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Table No.27: Dissolution profile of formulation F4 
Time in 
minute 
Cumulative Percent 
Drug Release(%) 
0 0 
5 50.5 
10 54.27 
15 60.06 
20 71.85 
25 74.97 
30 80.21 
 
Fig. No. 23. In-vitro dissolution study F4 
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Table No.28: Dissolution profile of formulation F5 
Time in minute 
Cumulative Percent 
Drug Release (%) 
0 0 
5 67.11 
10 73.45 
15 78.82 
20 83.14 
25 91.50 
30 98.12 
 
Fig. No. 24. In-vitro dissolution study F5 
 
 
 
0
10
20
30
40
50
60
70
80
90
0 5 10 15 20 25 30 35
Time in Minutes
Cu
m
m
u
la
tiv
e 
pe
rc
en
t d
ru
g 
re
le
as
e 
(%
)
Chapter 7  Results and Discussion 
Dept. of Pharmaceutics  87 J.K.K. Nattraja College of Pharmacy 
Table No.29: Dissolution profile of formulation F6 
Time in minute 
Cumulative Percent 
Drug Release(%) 
0.0 0 
5.0 67.14 
10 73.50 
15 78.87 
20 83.15 
25 91.50 
30 99.15 
 
Fig. No. 25. In-vitro dissolution study F6 
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Table No.30: Dissolution profile of formulation F7 
Time in minute 
Cumulative Percent 
Drug Release(%) 
0.0 0 
5.0 67.61 
10 73.74 
15 79.12 
20 84.36 
25 92.01 
30 99.50 
 
Fig. No. 26. In-vitro dissolution study F7 
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Table No.31: Dissolution profile of formulation F8 
Time in minute 
Cumulative Percent 
Drug Release(%) 
0.0 0 
5.0 67.80 
10 74.04 
15 79.75 
20 84.96 
25 92.80 
30 99.86 
 
Fig. No. 27. In-vitro dissolution study F8 
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Table No.32: Dissolution profile of formulation F9 
Time in minute 
Percent 
Drug Release(%) 
0.0 0 
5.0 67.01 
10 70.22 
15 77.44 
20 83.75 
25 91.76 
30 98.86 
 
Fig. No. 28. In-vitro dissolution study F9 
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Table No.33: Dissolution profile of formulation F10 
Time in minute 
Cumulative Percent 
Drug Release(%) 
0.0 0 
5.0 67.73 
10 70.91 
15 77.91 
20 84.01 
25 92.14 
30 99.06 
 
Fig. No. 29. In-vitro dissolution study F10 
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Table No.34: Dissolution profile of formulation F11 
Time in minute 
Cumulative Percent 
Drug Release(%) 
0.0 0 
5.0 66.11 
10 73.19 
15 78.78 
20 84.07 
25 91.23 
30 97.49 
 
Fig. No. 30. In-vitro dissolution study F11 
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Table No.35: Dissolution profile of formulation F12 
Time in minute 
Cumulative Percent 
Drug Release(%) 
0.0 0 
5.0 66.75 
10 73.85 
15 79.11 
20 84.50 
25 91.73 
30 98.01 
 
Fig. No. 31. In-vitro dissolution study F12 
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Table No :36 Comparative dissolution study F 1 – F 12 . 
TIME F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 0 0 0 0 0 0 
5 68.30 68.30 49.80 50.5 67.13 67.14 67.61 67.80 67.01 67.73 66.11 66.75 
10 74.02 74.06 53.82 54.27 73.48 73.50 73.50 74.04 70.23 70.91 73.19 73.85 
15 79.01 79.13 60.06 78.08 78.88 78.87 78.87 79.75 77.45 77.91 78.78 79.11 
20 85.15 85.16 71.85 84.39 83.17 83.15 83.15 84.96 83.76 84.01 84.07 84.50 
25 92.14 92.18 74.97 90.98 91.53 91.50 91.50 92.80 91.78 92.14 91.23 91.73 
30 99.91 99.93 80.21 97.28 98.17 99.15 99.15 99.50 98.06 97.49 97.49 98.01 
 
Fig. No. 32. Comparative dissolution study of F1 to F12 
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7.8.12. KINETIC STUDY OF OPTIMIZED FORMULATION  
 In-vitro release data was flatted in different kinetic model and given in table 
37 and figure 33 to 36.  
Table No: 37 
Time Log 
time 
Time
 
Cumulative 
% drug 
release 
Log 
cumulative 
% drug 
release 
Cumulative 
% drug 
remained 
Log 
cumulative 
% drug 
remained 
0 0 0 0 0 100 2 
5 0.697 2.23675 62.61 1.7963 37.29 1.5715 
10 1.0 3.16 69.84 1.8442 30.16 1.4794 
15 1.176 3.872 75.22 1.8763 24.77 1.3939 
20 1.301 4.471 81.31 1.9101 18.69 1.2716 
25 1.396 5.00 87.34 1.9412 12.64 1.1022 
30 1.477 5.477 93.73 1.9717 6.26 0.7965 
 
Table No. 37 Kinetic data of Optimized Fomulation F2 
 
Fig. No. 33 : ZERO ORDER 
 
Y = 2.173X + 33.22
R² = 0.723
0
20
40
60
80
100
120
0 5 10 15 20 25 30 35 40
C
U
M
U
LA
TI
V
E 
PE
R
C
EN
T 
D
R
U
G
 
R
EL
EA
SE
TIME (HRS)
ZERO ORDER
Chapter 7  Results and Discussion 
Dept. of Pharmaceutics  96 J.K.K. Nattraja College of Pharmacy 
Fig. No. 34 : FIRST ORDER 
 
 
Fig. No. 35 : HIGUCHI 
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Fig. No. 36 : KORSEMEYER PEPPAS PLOT 
 
 
The above studies showed that the drug release follows first order kinetics. 
7.9. STABILITY STUDY 
Optimized formulation (F2) was subjected to stability studies at 40oc± 
2oc/75% RH ±5 % for 90 days. The product was evaluated for appearance and 
hardness, friability, disintegration. Drug release studies were conducted as per the 
planned scheduled as above. 
7.9.1. Descriptions: 
Table No.38: Description 
Storage 
condition Test Observation Inference 
RT Descriptions No change of color in all 
strengths 
Complies with stability 
condition 
40oC + 2oC/ 
75% RH Descriptions 
No change of color in all 
strengths 
Complies with stability 
condition 
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7.9.2. Stability parameters of formulation F2 stored at 40oC + 2oC/ 75% RH 
 The results were illustrated in following table no. 39. 
Table No.39:  
Sr. 
No. 
Parameters Initial 30 days 60 days 90 days 
1 % Friability 0.274 0.271 0.270 0.273 
2 Hardness (kg / cm2) 3.0 2.7 3.1 3.2 
3 Drug Content (%) 100.01 99.13 98.51 98.21 
4 In-Vitro Disin. 
Time(Sec) 38 41 42.24 44.11 
 
 All results complies with the stability condition 
7.9.3. In-vitro Dissolution study  
 It was done as per procedure given in material and method part. The results were 
illustrated in following table no. 45. 
Storage Condition at 40oC + 2oC 
Table No.40: In-vitro dissolution study 
Formulation 
(F2) 
Percentage Drug Release After 30 minutes 
Initial (0 Days) 30 Days 60 Days 90 Days 
99.83 99.24 98.84 98.40 
 
The results showed that there was no significant change in physical and 
chemical parameter of the tablet, hence the formulation was found to be stable. 
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Fig. No. 37: In-vitro dissolution study F2 dissolution study
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8. SUMMARY AND CONCLUSION 
SUMMARY 
 In the present study immediate release drug delivery system of nebivolol 
were successfully developed in the form of mouth dissolving tablets with improved 
dissolution characteristic by forming solid dispersion with PEG 6000, which offers a 
suitable and practical approach in serving desired objective of faster disintegration 
and dissolution characteristics with increase bioavailability. Immediate release 
tablets of nebivolol were prepared by using natural superintegrants like 
microcrystalline cellulose, croscarmellose sodium, crospovidone, sodium starch 
glycolate and their combination as superdisintegrants. 
 Superdisintegrants work as an auxiliary or as a facilitator of the flowability 
and compressibility of the mixture and contribute to the fast dispersion of the tablet, 
due to its high solubility in water. 
 For the nebivolol formulation, batch No. 2 was chosen as it has 
disintegration time around 5-35 seconds and hardness3.5 Kg/Cm2. IR spectra of drug 
with other excipients has not shown any interaction and also selected formulation 
was stable after stability studies. 
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CONCLUSION 
The solubility and dissolution rate of nebivolol can be enhanced by 
formulating SDs of nebivolol with PEG 6000.The solubilization effect of PEG 6000, 
reduction of particle aggregation of the drug, formation of microcrystalline or 
amorphous drug, increased wettability and dispersibility, and alteration of the 
surface properties of the drug particles might be responsible for the enhanced 
solubility and dissolution rate of nebivolol from its SD and to some extent in PMs. 
No endothermic peak of nebivolol was present in of SDs with PEG 6000 suggesting 
the absence of crystalline nebivolol. From FTIR spectroscopy, it was concluded that 
there was no well defined chemical interaction between nebivolol and PEG 6000 in 
SDs and in PMs, as no important new peaks could be observed. 
The identical composition of Superdisintegrants showed that a substantial 
shorter time require for disintegration can be obtained and immediate release tablet 
were prepared. The nebivolol immediate release tablet (F2) showed 68.30% drug 
release within first 5 min. and 99.93% drug release with in 30 min.  
 The results showed that the formulation satisfied the objective of fast 
disintegration, dissolution, % friability, hardness, wetting time, water absorption 
ratio, ease of administration and safety. 
 Success of the present study recommends a detailed investigation in to in-
vivo studies for its effective use in clinical practice. 
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